Search results for "anti-inflammatory agents"

showing 10 items of 576 documents

Mesalazine for the treatment of inflammatory bowel disease

2013

Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…

medicine.medical_specialtyColorectal cancerDiseaseGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseMesalazineInternal medicineSecondary PreventionmedicineHumansPharmacology (medical)Intestinal MucosaColitisMesalaminePharmacologyCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.diseaseUlcerative colitischemistryTolerabilityColitis UlcerativeColorectal NeoplasmsbusinessExpert Opinion on Pharmacotherapy
researchProduct

Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Objective We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as w…

medicine.medical_specialtyDICLOFENAC SODIUM GELDiclofenacDrug-Related Side Effects and Adverse ReactionsMedDRAVEHICLE TDT 064MEDLINEOsteoarthritisKNEE OSTEOARTHRITISAdministration CutaneousPlaceboLONG-TERM USE03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePharmacotherapyInternal medicineOsteoarthritisHumansMedicinePharmacology (medical)030212 general & internal medicineAdverse effectRandomized Controlled Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-SteroidalTRANSFERSOME GELOdds ratiomedicine.diseaseEFFICACYRANDOMIZED CLINICAL-TRIALORAL CELECOXIBTreatment OutcomeMeta-analysisSystematic ReviewGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryTASK-FORCE
researchProduct

Helicobacter pyloriand Non-malignant Diseases

2008

In 2007 Helicobacter pylori research continued to deal with some controversies raised in the last decade. The main problems remain unsolved: peptic ulcer disease negative for H. pylori, synergism of H. pylori infection and aspirin and other nonsteroidal anti-inflammatory drugs or cyclooxygenase 2 specific inhibitors, the role of H. pylori eradication in uninvestigated and nonulcer dyspepsia, and the possible protective effect of H. pylori infection against gastroesophageal reflux disease and its complications such as Barrett's esophagus and adenocarcinoma. The incidence and prevalence of peptic ulcer disease as well as ulcer-related mortality are continuing to decline all over the world. Th…

medicine.medical_specialtyGastrointestinal DiseasesDiseaseGastroenterologyHelicobacter InfectionsPathogenesisInternal medicinemedicineHumansDyspepsiaEsophagusAspirinHelicobacter pyloribiologybusiness.industryIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalGastroenterologyGeneral MedicineHelicobacter pylorimedicine.diseasebiology.organism_classificationdigestive system diseasesInfectious Diseasesmedicine.anatomical_structureGERDAdenocarcinomabusinessmedicine.drugHelicobacter
researchProduct

Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt

1990

The clinical progression of the cataract may be influenced by drugs which reduce the denaturation of lens proteins. One of the most promising drugs is the bendazac-lysine salt. The drug was used in a double-blind study of a group of patients with initial cortical cataract in order to evaluate the changes in visual acuity and contrast sensitivity by means of a psychophysical and an electrophysiological method. After 6 months of treatment with bendazac the mean values of visual acuity showed a statistically significant increase in respect to baseline values, as well as an improvement of the threshold of contrast for most spatial frequencies. In the eyes treated with placebo there was no stati…

medicine.medical_specialtyIndazolesVisual acuitygenetic structuresEye diseasemedia_common.quotation_subjectVisual AcuityPlaceboCataractContrast SensitivityLens proteinDouble-Blind MethodOral administrationPhysiology (medical)OphthalmologyBendazacPsychophysicsmedicineHumansContrast (vision)media_commonbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseeye diseasesSensory SystemsSurgeryElectrophysiologyOphthalmologyElectrophysiologyEvoked Potentials Visualmedicine.symptombusinessPhotic Stimulationmedicine.drugDocumenta Ophthalmologica
researchProduct

Intra-operative locally injected pharmacotherapy as a novel strategy for adhesion prophylaxis.

2012

Abstract Background Pharmacotherapy for peritoneal adhesion prophylaxis has been a focus for intensive research. Previous strategies included intravenous and intraperitoneal application of suitable pharmaceutical agents. However, success of these strategies in humans has been limited. Here we describe intra-operative local injection of pharmaceuticals as a novel strategy for adhesion prophylaxis. Methods N  = 208 peritoneal lesions were created in 26 adult Wistar rats. In each animal, lesions on one flank were randomly chosen for treatment with locally injected prednisolone whereas the contralateral side was injected with normal saline. Half of the animals were randomly selected for early a…

medicine.medical_specialtyIntra operativeAdhesionsmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdhesion (medicine)Tissue AdhesionsPeritoneal DiseasesStatistics NonparametricRandom AllocationPharmacotherapyLocal injectionStatistical significanceAbdomenmedicineAnimalsLocal anesthesiaRats WistarSteroidSalineIntraoperative Carebusiness.industryHistocytochemistryGeneral Medicinemedicine.diseaseSurgeryRatsDisease Models AnimalPrednisoloneSurgeryPeritoneumbusinessLocal injectionInjections Intraperitonealmedicine.drugInternational journal of surgery (London, England)
researchProduct

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

2021

AbstractWe conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included.…

medicine.medical_specialtyIntraocular pressuregenetic structuresSciencemedicine.medical_treatmentAnti-Inflammatory AgentsArticleMacular Edema03 medical and health sciences0302 clinical medicineDiabetes complicationsFluocinolone acetonideOphthalmologymedicineGlaucoma surgeryHumans030212 general & internal medicineGlucocorticoidsIntraocular PressureDrug ImplantsDiabetic RetinopathyMultidisciplinarybusiness.industryQRCataract surgeryRetinal diseaseseye diseasesConfidence intervalFluocinolone AcetonideDiabetic macular oedemaMeta-analysis030221 ophthalmology & optometryMedicinesense organsImplantbusinessmedicine.drugScientific Reports
researchProduct

Nanocapsules generated out of a polymeric dexamethasone shell suppress the inflammatory response of liver macrophages.

2012

Abstract Dexamethasone (DXM) is a synthetic glucocorticoid with anti-inflammatory properties. Targeted delivery of dexamethasone to inflammatory cells, e.g. macrophages and Kupffer cells represents a promising approach to minimize side effects. The aim of the present study was to induce a targeted transport of novel DXM-based biodegradable nanocapsules to phagocytic cells. Nanocapsules (NCs) consisting of a hydroxyethylated glucose polymer (hydroxyethyl starch, HES) shell with encapsulated DXM and NCs synthesized exclusively in inverse miniemulsion out of DXM were investigated. Non-parenchymal murine liver cells served as target cells. HES-DXM NCs were predominantly incorporated by Kupffer …

medicine.medical_specialtyMaterials sciencemedicine.drug_classKupffer CellsInflammatory responseBiomedical EngineeringAnti-Inflammatory AgentsPharmaceutical ScienceMedicine (miscellaneous)BioengineeringStimulationHydroxyethyl starchPharmacologybehavioral disciplines and activitiesNanocapsulesDexamethasoneProinflammatory cytokineHydroxyethyl Starch DerivativesMiceDrug Delivery SystemsNanocapsulesInternal medicinemental disordersmedicineAnimalsGeneral Materials ScienceDexamethasoneCells CulturedMice Inbred C57BLEndocrinologyMolecular MedicineCorticosteroidCytokinesFemaleGlucocorticoidmedicine.drugNanomedicine : nanotechnology, biology, and medicine
researchProduct

Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein

2008

<i>Background:</i> Epidemiological studies have suggested that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of Alzheimer’s disease (AD). Several mechanisms have been proposed to explain these findings including increased shedding of the soluble ectodomain of the amyloid precursor protein (sAPP), which functions as a neurotrophic and neuroprotective factor in vitroand in vivo. <i>Objective:</i> To clarify whether NSAIDs consistently stimulate sAPP secretion. <i>Methods:</i> 293-EBNA cells with stable overexpression of an APP-alkaline phosphatase fusion protein (APP-AP), SH-SY5Y and PC12 cells or prim…

medicine.medical_specialtyMedizinische Fakultät -ohne weitere Spezifikation-IndomethacinIbuprofenStimulationCHO Cells-PC12 CellsNeuroprotectionCell LineAmyloid beta-Protein PrecursorNeuroblastomaCricetulusWestern blotDownregulation and upregulationCell Line TumorCricetinaeInternal medicinemedicineAmyloid precursor proteinAnimalsddc:610medicine.diagnostic_testbiologyChemistryAnti-Inflammatory Agents Non-SteroidalTransfectionAlkaline PhosphataseRatsKineticsEndocrinologyNeurologyEctodomainCell culturebiology.proteinTetradecanoylphorbol AcetateNeurology (clinical)
researchProduct

Bronchodilator and anti-inflammatory activities of SCA40: studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo.

1998

There is currently interest in the use of inhibitors of cyclic nucleotide phosphodiesterases (PDE) as potential anti-asthma agents. In this study we examined the effects of SCA40 (6-bromo-8-methylaminoimidazol-[1,2-a] pyrazine-2-carbonitrile), a preferential inhibitor of PDE 3 also endowed with PDE 4 and 5 inhibitory activities, on isolated bronchus and eosinophil functions and in an animal model of asthma. SCA40 (1 nM-0.1 mM) produced concentration-dependent inhibition of spontaneous and stimulated tone of human isolated bronchus and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 against spontaneous tone (6.52 +/- 0.10) was grea…

medicine.medical_specialtyMuscle RelaxationGuinea PigsBronchiIn Vitro Techniqueschemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsHumansTheophyllineAntigensRolipramPharmacologyLeukotrieneLeukotriene C4Anti-Inflammatory Agents Non-SteroidalImidazolesMuscle SmoothGeneral MedicineEosinophilLeukotriene C4Bronchodilator AgentsEosinophilsmedicine.anatomical_structureEndocrinologychemistryPyrazinesBronchoconstrictionmedicine.symptomBronchial HyperreactivityHistaminemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches

2018

Abstract Background Primary headache are prevalent and debilitating disorders. Acute pain cessation is one of the key points in their treatment. Many drugs have been studied but the design of the trials is not usually homogeneous. Efficacy of the trial is determined depending on the selected primary endpoint and usually other different outcomes are measured. We aim to critically appraise which were the employed outcomes through a systematic review. Methods We conducted a systematic review of literature focusing on studies on primary headache evaluating acute relief of pain, following the PRISMA guideline. The study population included patients participating in a controlled study about sympt…

medicine.medical_specialtyNeurologyHeadache Disorders Primaryendpointspractice guidelines as topiclcsh:MedicineTriptansPlacebopatient complianceanti-inflammatory agentsnon-steroidal03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineprimarymedicineClinical endpoint030212 general & internal medicinehumansdisabled personsclinical trialsnon-steroidal anti-inflammatorybusiness.industryAnti-Inflammatory Agents Non-Steroidallcsh:RtryptaminesCorrectionacuteGeneral MedicineGuidelineacute; clinical trials; endpoints; non-steroidal anti-inflammatory; primary headaches; prisma-guidelines; triptans; anti-inflammatory agents non-steroidal; chronic disease; disabled persons; headache disorders primary; humans; patient compliance; practice guidelines as topic; treatment outcome; tryptamines; quality of lifemedicine.diseasetriptansClinical trialAnesthesiology and Pain Medicineheadache disordersMigrainequality of lifetreatment outcomeprimary headachesNeurology (clinical)prisma-guidelinesbusinesschronic disease030217 neurology & neurosurgeryResearch Articlemedicine.drug
researchProduct